Logo

AbbVie's Humira (adalimumab) Receives the US FDA's Approval to Treat Pediatric Patients with Ulcerative Colitis

Share this

AbbVie's Humira (adalimumab) Receives the US FDA's Approval to Treat Pediatric Patients with Ulcerative Colitis

Shots:

  • The approval is based on P-III ENVISION I study that involves assessing Humira (SC) vs PBO in pediatric patients aged 4-17yrs. with mod. to sev. UC
  • The study demonstrated that 60% of patients taking the higher dosage achieved clinical remission per PMS @8wks induction period and 45% of patients who responded @8wks- achieved remission per FMS @52wks.
  • Humira is the 1st and only SC biologic treatment option for pediatric patients with the mod. to sev. active UC. The approval marks the 11 indication in the US which includes 5 approval in pediatric populations

 ­ Ref: Abbvie | Image: Abbvie

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions